Abstract
Alzheimer's disease (AD) is one of the most serious neurodegenerative diseases and is characterized by progressive cognitive impairment and multiple neurological changes. To date, there are no effective drugs to delay or cure AD. Breviscapine (Bre) is an active ingredient of flavonoids extracted from breviscapus. Previous research suggests that Bre is an effective medicine for the prevention and treatment of AD. In the present study, we sought to explore the molecular mechanisms responsible for short-term beneficial effects of Breviscapine on Aβ burden, neuronal and synaptic, cognitive function in APP/PS1 transgenic mice at 6 months age. Our results showed that 3 months of intraperitoneal treatment with Bre rescued learning deficits, relieved memory retention, improved the ability to explore the outside world, markedly decreased Aβ burden, attenuated function of neocortical and hippocampal neuron, and increased the synaptic proteins levels in the brain of APP/PS1 mice by decreasing BACE1, promoting Aβ-degrading enzyme IDE expression, suppressing RAGE expression, and regulating p38/p53/NT4 pathway. This finding provides more evidence of neuroprotective effects and action mechanisms of Bre antagonist AD, suggesting that Bre may h...Continue Reading
References
Jan 1, 1996·Neuron·T J Carew
Oct 1, 1996·The Journal of Clinical Investigation·F M LaFerlaG Jay
May 5, 2001·Biomolecular Engineering·J L JankowskyD R Borchelt
Mar 14, 2003·Proceedings of the National Academy of Sciences of the United States of America·Wesley FarrisSuzanne Guenette
Jun 17, 2003·Nature Medicine·Rashid DeaneBerislav Zlokovic
Dec 23, 2003·Neuron·Malcolm A LeissringDennis J Selkoe
Aug 6, 2004·Nature·Mark P Mattson
Sep 1, 2005·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Angelika BierhausPeter P Nawroth
Sep 28, 2005·Neurochemical Research·Carl W Cotman
Jan 25, 2007·Nature Reviews. Molecular Cell Biology·Christian Haass, Dennis J Selkoe
Mar 3, 2007·Neurobiology of Aging·Dione KobayashiKaren S Chen
Nov 18, 2009·Neuropharmacology·Yan HouYuan Luo
Jul 9, 2010·Lancet Neurology·Francesca MangialascheMiia Kivipelto
Nov 25, 2011·International Journal of Alzheimer's Disease·Tarja MalmKatja Kanninen
Nov 29, 2011·Experimental Neurology·Nicole SchonrockJürgen Götz
Apr 20, 2012·Expert Opinion on Therapeutic Patents·Gary Probst, Ying-zi Xu
Mar 26, 2013·Journal of Clinical Pathology·Barnabas James Gilbert
May 23, 2014·Frontiers in Neurology·Yue-Qin ZengXin-Fu Zhou
Nov 21, 2014·Lupus·S L YuL S Tam
Mar 20, 2015·BioMed Research International·Teng JiangJin-Tai Yu
Apr 14, 2015·Journal of Neurochemistry·Wenbin WanShijin Xia
Dec 8, 2016·Lancet· The Lancet
Jan 8, 2017·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Anders GustavssonAnders Wimo
Apr 13, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Yue-Qin ZengXin-Fu Zhou
Jul 23, 2018·Molecular Neurobiology·Md Sahab UddinGhulam Md Ashraf
Nov 6, 2018·Mutation Research. Genetic Toxicology and Environmental Mutagenesis·Shomereeta RoyBirendranath Banerjee
Nov 20, 2018·Neuropharmacology·Rebeca LapresaAngeles Almeida
Nov 30, 2018·International Journal of Molecular Sciences·Anna Reustle, Michael Torzewski